Abstract
Historically, the treatment of adults with acute myelogenous leukemia (AML) has evolved through a number of phases. In the initial phase we saw the accumulation of information on the natural history of acute leukemia and study of the patterns of survival [1, 2]. Analysis of survival data in patients with acute leukemia who were treated with supportive care only was adequately documented and showed that half of all patients would die in less than four months and less than one patient in ten would live for one year. The early literature was concerned with documentation of spontaneous remissions, and up until 1960, there was no evidence that chemotherapy-induced remissions were of longer duration [1, 2] than those which occurred spontaneously. In addition, no accurate estimate of the response rate to chemotherapeutic agents was available, despite the fact that the ‘chemotherapy era’ in acute leukemia had been ushered in by Farber in 1949 [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tivey H: The natural history of untreated acute leukemia. Ann NY Acad Sci 60:322–358, 1954.
Southam CM, Craver LF, Dargeon HW, et al.: A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions. Cancer 4:39–59, 1951.
Boggs DR, Wintrobe MM, Cartwright GE: To treat or not to treat acute granulocytic leukemia. II. Arch Intern Med 123:568–570, 1969.
Farber S: Some observations on the effect of folic acid antagonists on acute leukemia and other forms of cancer. Blood 4:160, 1949.
Freireich EJ, et al.: The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14:593–607, 1961.
Boggs DR, Wintrobe MM, Cartwright GE: The acute leukemias: an analysis of 322 cases and review of the literature. Medicine 41:163–225, 1962.
Freireich EJ, Bodey GP, Harris JE, Hart JS: Therapy for acute granulocytic leukemia. Cancer Res 27:2573–2577, 1967.
Levin RH, Henderson E, Karon M, Freireich EJ: Treatment of acute leukemia with methyl-glyoxal-bis-guanylhydrazone (methyl GAG). Clin Pharmacol Ther 6:31–42, 1964.
Crosby WH: To treat or not to treat acute granulocytic leukemia. Arch Intern Med 122:79–80, 1968.
Ellison RR, Holland JF, Weil M, Jacquillat C: Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32: 307–523, 1968.
Bodey GP, et al.: Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother Rep 53:59–65, 1969.
Boiron M, Jacquillat C, Weil M, Tanzier J, Levy D, Sultan C, Bernard J: Daunorubicin in the treatment of acute myelocytic leukemia. Lancet i: 330, 1969.
Jacquillat C, Boiron M, Weil M, Tanzer J, Najean Y, Bernard J: Rubidomycin, a new agent active in the treatment of acute lymphoblastic leukaemia. Lancet ii: 27, 1966.
Burgess MA, Garson OM, De Gruchy GC: Daunorubicin in the treatment of adult acute leukaemia. Med J Aus 1:629–635, 1970.
Burchenal JH: Formal discussion: Long-term survival in Burkitt’s tumor and in acute leukemia. Cancer Res 27:2616–2618, 1967.
Southwest Oncology Group: cytarabine for acute leukemia in adults: effects of schedule on therapeutic response. Arch Intern Med 133:251–259, 1974.
Goodell B, Leventhal B, Henderson E: Cytosine arabinoside in acute granulocytic leukemia. Clin Pharmacol Ther 12:599–606, 1971.
Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J, O’connell MJ, Fortner C: Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrime-thamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Cancer Treat Rep 60:41–53, 1976.
Weil M, Glidewell OJ, Jacquillat C, Levy R: Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 33:921–928, 1973.
McCredie KB, Bodey GP, Freireich EJ, Hester JP: Chemoimmunotherapy of adult acute leukemia. Cancer (in press).
Jacquillat CL, Weil M, Gemon-Aucler MF, Izrael V: Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies. Cancer 37:653–659, 1976.
Gale RP, Cline MJ: High remission-induction rate in acute myeloid leukaemia. Lancet i:497–499, 1977.
Peterson BA, Bloomfield CD, Bosl GJ, Gibbs G, Malloy M: Intensive five-drug combination chemotherapy for adult acute nonlymphocytic leukemia. Cancer 46:663–668, 1980.
Preisler HD, Rustum Y, Henderson ES, Bjornsson S, et al.: Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:455–464, 1979.
Glucksberg H, Buckner CD, Fefer A, DeMarsh Q, Coleman D, et al.: Combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer Chemother Rep 59:1131–1137, 1975.
Keating MJ, Smith TL, McCredie KB, Bodey GP, et al.: A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer (in Press).
Ohno R, Hirano M, Imai K, Katsuo K, et al.: Daunorubicin, cytosine arabinoside, 6-mer-captopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myel-ogenous leukemia in adults. Cancer 36:1945–1949, 1975.
Bernard J, Weil M, Boiron M, et al.: Acute promyelocytic leukemia. Blood 41:489–496, 1973.
Reiffers J, Raynal F, Broustet A: Acute myeloblastic leukemia in elderly patients. Treatment and prognostic factors. Cancer 45:2816–2820, 1980.
Grann V, Erichson R, Flannery J, Finch S, Clarkson B: The therapy of acute granulocytic leukemia in patients more than 50 years old. Ann Intern Med 80:15–20, 1974.
Peterson BA, Bloomfield CD: Treatment of acute non-lymphocytic leukemia in elderly patients. A prospective study of intensive chemotherapy. Cancer 40:647–652, 1977.
Keating MJ, Benjamin RS, McCredie KB, Bodey GP, Freireich EJ: Remission induction therapy with a rubidazone-containing combination (ROAP) in acute leukemia. Proc Am Assoc Cancer Res 18:180, 1977 (Abst. # 719).
Yamada K, Uetani T: Five-Year survivors with acute leukemia in Japan. Acta Haematol Jap 37:99–107, 1974.
Jacquillat CI, Weil M, Gemon M-F, et al.: Evaluation of 216 four-year survivors of acute leukemia. Cancer 32:286–293, 1973.
Pavlovsky S, Muriel FS: Long-term survival in acute leukemia in Argentina. Cancer 40:1402–1409. 1977.
Oliff A, Poplack D: Characteristics of long-term survivors in AML. Med Pediatr Oncol 5:219–223, 1973.
Keating MJ, Bodey GP, McCredie KB, Freireich EJ: Five-year survival and remission duration in adult acute myelogenous leukemia. Proc Am Soc Clin Oncol 20:416, 1979 (Abstract).
Coltman CA, Jr, Freireich EJ, Savage RA, Gehan EA: Long term survival of adults with acute leukemia. Proc Am Soc Clin Oncol 20:389, 1979 (Abstract).
Ellison RR, Glidewell O: Improved survival in adults with acute myelocytic leukemia (AML). Proc Am Assoc Cancer Res 20:161, 1979 (Abstract).
Weil M, Auclerc MF, Jacquillat CL, et al.: Long term relapse free survivals (R.F.S.) in 815 patients (pts) with acute granulocytic leukemias (A.G.L.). Proc Am Soc Clin Oncol 21:444, 1980 (Abstract C-494).
Hewlet JS, Bodey GP, Wilson HE: Combination 6-mercaptopurine and 6-methylmercapto-purine riboside in the treatment of adult acute leukemia: a Southwest Oncology Group study. Cancer Treat Rep 63:156–158, 1979.
Rodriguez V, Hart JS, Freireich EJ, et al.: POMP combination chemotherapy of adult acute leukemia. Cancer 32:69–75, 1973.
Bodey GP, Rodriguez V, Hart J, et al.: Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). Cancer Chemother Rep 54:255–262, 1970.
Whitecar JP, Jr, Bodey GP, McCredie KB, et al.: Cyclophosphamide, vincristine, arabinosyl cytosine and prednisone (COAP) combination chemotherapy for adult acute leukemia. Cancer Chemother Rep 56:543–550, 1972.
Rogriguez V, Bodey GP, Gutterman JU, et al.: Combination chemotherapy of adult acute leukemia for remission induction and maintenance. In: Therapy of acute leukemias, Mandelli F, Amadori S, Mariani E (eds). Rome: Minerva Medica, 1973, pp 569–577.
McCredie KB, Freireich EJ, Bodey GP, Burgess MA, et al.: A study of intermittent alternating drug program reinduction therapy on the frequency and duration of response in adult acute leukemia. Med Pediatr Oncol 2:309–318, 1976.
Bodey GP, Rodriguez V, McCredie KB, et al.: Early consolidation chemotherapy for adults with acute leukemia in remission. Med Pediatr Oncol 2:299–307, 1975.
Bodey GP, Freireich EJ, Gehan E, et al.: Late intensification therapy for acute leukemia in remission. Chemotherapy and Immunotherapy. JAMA 235:1021–1025, 1976.
Gutterman JU, Hersh EM, Rodriguez V, et al.: Chemoimmunotherapy of adult acute leukaemia: prolongation of remission in myeloblastic leukemia with B.C.G. Lancet ii: 1405–1409, 1974.
Burge PS, Richards JDM, Thampson DS, et al.: Quality and quantity of survival in acute myeloid leukaemia. Lancet 621–624, 1975.
Armitage JO, Burns CP: Long term results of maintenance therapy in adult acute nonlym-phoblastic leukemia (ANLL) using cytosine arabinoside and thioguanine: the effect of FAB subtype on outcome. Proc Am Soc Clin Oncol 21:439, 1980 (Abstract C-477).
Peterson BA, Bloomfield CD: Long-term disease-free survival in acute non-lymphocytic leukemia. Blood 57:1144–1147, 1981.
Clarkson BD, Dowling MD, Gee TS, Cunningham IB, Burchenal JH: Treatment of acute leukemia in adults. Cancer 36:775–795, 1975.
Vaughan WP, Karp JE, Burke PJ: Long chemotherapy-free remissions after single-cycle times-sequential chemotherapy for acute myelocytic leukemia. Cancer 45:859–865, 1980.
Fiere D, Martin C, Van H-Vu, et al.: Leucémies myéloides aiguës survie supérieure à 3 ans chez 16 malades. La Nouvelle Pres Medicale 7:899–902, 1978.
Kawashima K, Suzuki H, Yamada K, et al.: Long-term survival in acute leukemia in Japan. A study of 304 cases. Cancer 45:2181–2187, 1980.
Keating MJ, Smith TL, Gehan EA, et al.: Factors related to length of complete remission in adult acute leukemia. Cancer 45:2017–2029, 1980.
Gehan EA, Smith TL, Freireich EJ, et al.: Prgnostic factors in acute leukemia. Semin Oncol 3:271–282, 1967.
Henderson ES, Wallace HJ, Yates J, Scharlaw C et al.: Factors influencing prognosis in adult acute myelocytic leukemia. In: Advances in the biosciences, workshop on prognostic factors in human acute leukemia, Vol. 14, Fliedner TM, Perry S (eds). New York: Pergamon Press, 1975, pp 71–82.
Golomb HM, Rowley JD, Vardiman JW, Testa JR, Butler A: ‘Microgranular’ acute promyelocytic leukemia: a distinct clinical, ultra-structural, and cytogenetic entity. Blood 55:253–259, 1980.
Golomb HM, Rowley JD, Vardiman JW, Baron MM, Locker G, Krasnow S: Partial delection of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Intern Med 136:825–828, 1976.
Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB: Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood 53:695–706, 1979.
Hoelzer D, Kurrle E, et al.: Evidence for differentiation of human leukemic blood cells in diffusion chamber culture. Blood 49:729–744, 1977.
Barton JC, Conrad ME: Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 90:188–190, 1979.
Wade JC, Wiernik PH, Schimpff SC, Schiffer CA: Hepatitis prolongation of complete remission and survival in acute nonlymphocytic leukemia (ANLL) patients. Proc Am Soc Clin Oncol 21:439, 1980 (Abstract C-474).
Dudley FJ, Fox RA, Sherlock S: Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet i:723–726, 1972.
Werner B, London WT: Host responses to hepatitis B infection: hepatitis B surface antigen and host proteins (editorial). Ann Intern Med 83:113–114, 1975.
Sakurai M, Sandberg AA: Chromosomes and causation of human cancer and leukemia. Correlation of karyotypes with clinical features of acute myeloblastic leukemia. Cancer 37:285–299, 1976.
Freireich EJ, Keating MJ, Gehan EA, McCredie KB, Bodey GP, Smith T: Therapy of acute myelogenous leukemia. Cancer 42:874–882, 1978.
Rees JKH, Sandier RM, Challener J, Hayhoe FGJ: Treatment of acute myeloid leukaemia with a triple cytotoxic regimen: DAT. Br J Cancer 36:770–776, 1977.
Uzuka Y, Liong SK, Yamagata S: Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone DCMP two step therapy. Tohoku J Exp Med 118:217–225, 1976.
Bodey GP, McCredie KB, Keating MJ, Freireich EJ: Treatment of acute leukemia in protected environment units. Cancer 44:431–436, 1979.
Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ: 4′-(9-acridinyl-amino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med 93:17–21, 1980.
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, et al.: Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303:473–478, 1980.
Thomas ED, Buckner CD, Clift RA, et al.: Marrow transplantation for acute nonlympho-blastic leukemia in first remission. N Engl J Med 301:597–599, 1979.
Blume KG, Beutler E, Bross KJ, et al.: Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302:1041–1046, 1980.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Martinus Nijhoff Publishers bv, The Hague
About this chapter
Cite this chapter
Keating, M.J. (1982). Early Identification of Potentially Cured Patients with Acute Myelogenous Leukemia — A Recent Challenge. In: Bloomfield, C.D. (eds) Adult Leukemias 1. Cancer Treatment and Research, vol 5. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7433-3_8
Download citation
DOI: https://doi.org/10.1007/978-94-009-7433-3_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-7435-7
Online ISBN: 978-94-009-7433-3
eBook Packages: Springer Book Archive